PDT Partners’s Kiniksa Pharmaceuticals KNSA Stock Holding History

PDT Partners’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.59M	Sell	40,567 -39,696	-49%	-$2.06M	0.14%	213
2026 Q1	$3.86M	Sell	80,263 -21,359	-21%	-$946K	0.23%	147
2025 Q4	$4.19M	Hold	101,622	–	–	0.27%	133
2025 Q3	$3.95M	Sell	101,622 -1,264	-1%	-$41.1K	0.25%	147
2025 Q2	$2.85M	Buy	102,886 +56,479	+122%	+$1.44M	0.16%	220
2025 Q1	$1.03M	Sell	46,407 -18,510	-29%	-$381K	0.07%	387
2024 Q4	$1.28M	Buy	64,917 +27,675	+74%	+$632K	0.11%	289
2024 Q3	$931K	Buy	+37,242	New	+$907K	0.08%	383
2023 Q3	–	Sell	-40,439	Closed	-$569K	–	637
2023 Q2	$569K	Hold	40,439	–	–	0.08%	357
2023 Q1	$435K	Buy	40,439 +12,131	+43%	+$160K	0.06%	411
2022 Q4	$424K	Sell	28,308 -6,439	-19%	-$93.8K	0.07%	418
2022 Q3	$446K	Sell	34,747 -16,632	-32%	-$189K	0.07%	468
2022 Q2	$498K	Sell	51,379 -14,897	-22%	-$139K	0.04%	603
2022 Q1	$659K	Buy	+66,276	New	+$702K	0.06%	500

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

PDT Partners's KNSA Position: Q2 2026 in Review

PDT Partners reduced its Kiniksa Pharmaceuticals (KNSA) stake by 49% in Q2 2026, selling an estimated $2.06M and leaving 40,567 shares worth $2.59M. The position accounts for 0.14% of the portfolio, ranked #213.

PDT Partners first reported a position in KNSA in Q1 2022 and has held it in 14 quarters since. The position peaked at $4.19M in Q4 2025. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

PDT Partners held 40,567 shares of Kiniksa Pharmaceuticals worth $2.59M as of Q2 2026.
PDT Partners sold 39,696 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $2.06M.
Kiniksa Pharmaceuticals made up 0.14% of PDT Partners's portfolio in Q2 2026, its #213 holding.
PDT Partners first reported a position in Kiniksa Pharmaceuticals in Q1 2022 and has held it in 14 quarters since.
PDT Partners's Kiniksa Pharmaceuticals position peaked at $4.19M in Q4 2025.
266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on PDT Partners's 13F filing for Q2 2026, filed 14 Aug 2026.